Larimar Therapeutics, Inc.
Larimar Therapeutics, Inc. (Nasdaq: LRMR) is a clinical-stage biotechnology company developing treatments for rare diseases using a cell-penetrating peptide technology platform designed to deliver therapeutic molecules inside cells. Its lead candidate, nomlabofusp, is an investigational subcutaneous fusion protein… From the company’s description.
In fiscal 2025, Larimar Therapeutics, Inc. reported a net loss of $165.67M. Operations used $113.20M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Larimar Therapeutics, Inc. does
In the company’s own words
Larimar Therapeutics, Inc. (Nasdaq: LRMR) is a clinical-stage biotechnology company developing treatments for rare diseases using a cell-penetrating peptide technology platform designed to deliver therapeutic molecules inside cells. Its lead candidate, nomlabofusp, is an investigational subcutaneous fusion protein designed to deliver frataxin to mitochondria in patients with Friedreich’s ataxia, a genetic disease associated with insufficient frataxin. The company’s research also aims to apply its platform to other rare and orphan diseases involving deficiencies or alterations in intracellular molecules or activity. Larimar has completed Phase 1 and Phase 2 studies of nomlabofusp in adults and a Phase 1 pharmacokinetic study in adolescents, and it is conducting an open-label study in adults and adolescents. The company operates as a single business focused on research and development; it has no commercial revenue. It reported $136.9 million in cash, cash equivalents and marketable securities at December 31, 2025.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- BALA CYNWYD, PA
- Fiscal year end
- December
- CIK
- 1374690
- SIC
- 2834
Financial performance, year by year
Fiscal 2014–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Larimar Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Larimar Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Larimar Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Larimar Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Larimar Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”